-+ 0.00%
-+ 0.00%
-+ 0.00%
Heplatinum Pharmaceutical-B (02142): LET003's new drug clinical trial application was accepted by the State Drug Administration
Share
Listen to the news

Zhitong Finance App News, and Platinum Pharmaceutical-B (02142) announced that the China National Drug Administration (China Drug Administration) has accepted the company's first new drug clinical trial (IND) application for the next-generation targeted ACVR2A/2B monoclonal antibody LET003 developed using the HU-Matrix™ AI platform to treat overweight or obesity. LET003 is a potentially best-in-class next-generation monoclonal antibody targeting activin receptors ACVR2A and ACVR2B, which play a key role in regulating the homeostasis of muscle-fat metabolism.

LET003 is the company's first AI-enabled drug candidate and aims to block ACVR2A and ACVR2B through dual targets. Preclinical studies have shown that LET003's pharmacokinetic characteristics are superior to many similar competitor molecules. When used in combination with simeglutide, LET003 can significantly enhance the fat loss effect while effectively maintaining lean body weight. Furthermore, LET003 can achieve lean-weight promotion effects comparable to high-dose Bimagrumab at lower dosage levels, demonstrating its potential to be the best-in-class treatment for overweight or obesity.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending